PL375889A1 - Związki do leczenia chorób proliferacyjnych, kompozycje zawierające te związki i ich zastosowanie - Google Patents

Związki do leczenia chorób proliferacyjnych, kompozycje zawierające te związki i ich zastosowanie

Info

Publication number
PL375889A1
PL375889A1 PL03375889A PL37588903A PL375889A1 PL 375889 A1 PL375889 A1 PL 375889A1 PL 03375889 A PL03375889 A PL 03375889A PL 37588903 A PL37588903 A PL 37588903A PL 375889 A1 PL375889 A1 PL 375889A1
Authority
PL
Poland
Prior art keywords
compounds
application
compositions containing
proliferative diseases
cellular proliferative
Prior art date
Application number
PL03375889A
Other languages
English (en)
Inventor
Xiangping Qian
Gustave Bergnes
David J.Jr. Morgans
Steven David Knight
Dashyant Dhanak
Original Assignee
Cytokinetics, Inc.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Inc., Smithkline Beecham Corporation filed Critical Cytokinetics, Inc.
Publication of PL375889A1 publication Critical patent/PL375889A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03375889A 2002-10-11 2003-10-02 Związki do leczenia chorób proliferacyjnych, kompozycje zawierające te związki i ich zastosowanie PL375889A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41788902P 2002-10-11 2002-10-11

Publications (1)

Publication Number Publication Date
PL375889A1 true PL375889A1 (pl) 2005-12-12

Family

ID=32094113

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375889A PL375889A1 (pl) 2002-10-11 2003-10-02 Związki do leczenia chorób proliferacyjnych, kompozycje zawierające te związki i ich zastosowanie

Country Status (19)

Country Link
US (1) US7476743B2 (pl)
EP (1) EP1558588A4 (pl)
JP (1) JP2006502219A (pl)
KR (1) KR20050075356A (pl)
CN (1) CN1726198A (pl)
AR (1) AR044193A1 (pl)
AU (1) AU2003282665A1 (pl)
BR (1) BR0315247A (pl)
CA (1) CA2501938A1 (pl)
IL (1) IL167936A0 (pl)
IS (1) IS7798A (pl)
MX (1) MXPA05003830A (pl)
NO (1) NO20052267L (pl)
NZ (1) NZ539643A (pl)
PL (1) PL375889A1 (pl)
RU (1) RU2005114491A (pl)
TW (1) TW200418818A (pl)
WO (1) WO2004032840A2 (pl)
ZA (1) ZA200503733B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
BRPI0514390A (pt) 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
JP5343363B2 (ja) * 2008-01-31 2013-11-13 アイシン精機株式会社 シートクッション調整装置
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
US8546434B2 (en) 2010-04-15 2013-10-01 Novartis Ag Triazole compounds as KSP inhibitors
WO2012095691A1 (en) * 2011-01-15 2012-07-19 Jubilant Life Sciences Ltd. An improved process for producing aminopyridines
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
ES2660249T3 (es) 2012-12-20 2018-03-21 Inception 2, Inc. Compuestos de tipo triazolona y sus usos
JP2016529311A (ja) 2013-09-06 2016-09-23 インセプション ２、 インコーポレイテッド トリアゾロン化合物類及びそれらの使用
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
WO2023192499A1 (en) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Nucleosides for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793532A (fr) * 1971-12-29 1973-06-29 Upjohn Co Nouvelles 1,2,4-triazol-3-ones et leur preparation
US3748339A (en) * 1972-05-05 1973-07-24 Upjohn Co 2-(3-(1-(dimethylamino)alkyl)-1,5-dihydro-5-oxo - 1 - substituted-4h-1,2,4-triazol-4-yl)benzophenone and process
NO773853L (no) 1976-11-17 1978-05-19 Montedison Spa Nye fosforsyreestre avledet fra 1,2,4-triazol med insekticid, nematocid og acaricid virkning, og fremstilling av disse
IT1068010B (it) * 1976-11-17 1985-03-21 Montedison Spa Nuovi esteri fosforici derivati dall' 1-2-4 triazolo ad azione insetticida,nematocida e acaricida e loro preparazione
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB9211193D0 (en) * 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
WO1997014671A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Cyclopentyl tachykinin receptor antagonists
JP2002234874A (ja) * 2000-09-26 2002-08-23 Tanabe Seiyaku Co Ltd ５−フェニルベンジルアミン誘導体、その製法及びその合成中間体
JP2004512317A (ja) * 2000-10-26 2004-04-22 メルク　エンド　カムパニー　インコーポレーテッド タキキニン受容体拮抗薬の哺乳動物の代謝産物
KR20050010515A (ko) * 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제

Also Published As

Publication number Publication date
ZA200503733B (en) 2006-02-22
NO20052267L (no) 2005-05-31
JP2006502219A (ja) 2006-01-19
KR20050075356A (ko) 2005-07-20
RU2005114491A (ru) 2006-02-10
CA2501938A1 (en) 2004-04-22
WO2004032840A2 (en) 2004-04-22
WO2004032840A3 (en) 2004-10-14
TW200418818A (en) 2004-10-01
AR044193A1 (es) 2005-09-07
EP1558588A2 (en) 2005-08-03
NZ539643A (en) 2006-11-30
IL167936A0 (en) 2009-02-11
MXPA05003830A (es) 2005-06-23
US20060189671A1 (en) 2006-08-24
BR0315247A (pt) 2005-08-30
IS7798A (is) 2005-04-11
US7476743B2 (en) 2009-01-13
CN1726198A (zh) 2006-01-25
AU2003282665A1 (en) 2004-05-04
EP1558588A4 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
PL373412A1 (pl) Związki typu pirymidynonu, kompozycje zawierającete związki i sposoby ich wykorzystania do leczenia chorób związanych z rozrostem komórek
MY143799A (en) Compositions and methods for treating diabetes
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
AU2003262747A8 (en) Compounds, compositions, and methods
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
ZA200702226B (en) Compounds, compositions containing them, preparations thereof and uses thereof II
AU2003299612A8 (en) Compounds, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
ZA200500203B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
EP1709155A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF DYSPROLIFERATIVE DISEASES AND METHODS OF THEIR USE
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
HUP0401612A3 (en) Pharmaceutical composition suitable for treating diabetes
AU2003290507A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
GB0307695D0 (en) Compounds,compositions and processes
HUP0600855A2 (en) Androgen pharmaceutical composition for treating depression
AU2003224486A1 (en) Composition for treating cancer containing n,n-dimethylphytosphingosine
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2003300031A8 (en) Compounds, compositions, and methods
AU2003267169A8 (en) Compounds, compositions and methods
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
IL168059A0 (en) Benzopyranone compounds, compositions thereof, and methods for treating orpreventing cancer

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)